Literature DB >> 16374823

Widespread decrease of nicotinic acetylcholine receptors in Parkinson's disease.

Masahiro Fujita1, Masanori Ichise, Sami S Zoghbi, Jeih-San Liow, Subroto Ghose, Douglass C Vines, Janet Sangare, Jian-Qiang Lu, Vanessa L Cropley, Hidehiro Iida, Kyeong Min Kim, Robert M Cohen, William Bara-Jimenez, Bernard Ravina, Robert B Innis.   

Abstract

OBJECTIVE: Nicotinic acetylcholine receptors have close interactions with the dopaminergic system and play critical roles in cognitive function. The purpose of this study was to compare these receptors between living PD patients and healthy subjects.
METHODS: Nicotinic acetylcholine receptors were imaged in 10 nondemented Parkinson's disease patients and 15 age-matched healthy subjects using a single-photon emission computed tomography ligand [(123)I]5-iodo-3-[2(S)-2-azetidinylmethoxy]pyridine. Using an arterial input function, we measured the total distribution volume (V; specific plus nondisplaceable), as well as the delivery (K(1)).
RESULTS: Parkinson's disease showed a widespread significant decrease (approximately 10%) of V in both cortical and subcortical regions without a significant change in K(1).
INTERPRETATION: These results indicate the importance of extending the study to demented patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16374823      PMCID: PMC1351078          DOI: 10.1002/ana.20688

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  17 in total

1.  Strategies to improve neuroreceptor parameter estimation by linear regression analysis.

Authors:  Masanori Ichise; Hiroshi Toyama; Robert B Innis; Richard E Carson
Journal:  J Cereb Blood Flow Metab       Date:  2002-10       Impact factor: 6.200

Review 2.  Nicotinic receptors in aging and dementia.

Authors:  Marina R Picciotto; Michele Zoli
Journal:  J Neurobiol       Date:  2002-12

3.  Smoking and Parkinson's disease in twins.

Authors:  C M Tanner; S M Goldman; D A Aston; R Ottman; J Ellenberg; R Mayeux; J W Langston
Journal:  Neurology       Date:  2002-02-26       Impact factor: 9.910

4.  5-Iodo-A-85380, an alpha4beta2 subtype-selective ligand for nicotinic acetylcholine receptors.

Authors:  A G Mukhin; D Gündisch; A G Horti; A O Koren; G Tamagnan; A S Kimes; J Chambers; D B Vaupel; S L King; M R Picciotto; R B Innis; E D London
Journal:  Mol Pharmacol       Date:  2000-03       Impact factor: 4.436

5.  Loss of alpha-conotoxinMII- and A85380-sensitive nicotinic receptors in Parkinson's disease striatum.

Authors:  M Quik; T Bordia; L Forno; J M McIntosh
Journal:  J Neurochem       Date:  2004-02       Impact factor: 5.372

6.  Effects of SIB-1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in parkinsonian monkeys.

Authors:  J S Schneider; A Pope-Coleman; M Van Velson; F Menzaghi; G K Lloyd
Journal:  Mov Disord       Date:  1998-07       Impact factor: 10.338

7.  L-DOPA treatment modulates nicotinic receptors in monkey striatum.

Authors:  Maryka Quik; Tanuja Bordia; Michaella Okihara; Hong Fan; Michael J Marks; J Michael McIntosh; Paul Whiteaker
Journal:  Mol Pharmacol       Date:  2003-09       Impact factor: 4.436

8.  Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls.

Authors:  Emma J Burton; Ian G McKeith; David J Burn; E David Williams; John T O'Brien
Journal:  Brain       Date:  2004-01-28       Impact factor: 13.501

9.  5-Iodo-A-85380 binds to alpha-conotoxin MII-sensitive nicotinic acetylcholine receptors (nAChRs) as well as alpha4beta2* subtypes.

Authors:  Jennifer M Kulak; Jocelyn Sum; John L Musachio; J Michael McIntosh; Maryka Quik
Journal:  J Neurochem       Date:  2002-04       Impact factor: 5.372

10.  Quantification of nicotinic acetylcholine receptors in human brain using [123I]5-I-A-85380 SPET.

Authors:  Masahiro Fujita; Masanori Ichise; Christopher H van Dyck; Sami S Zoghbi; Gilles Tamagnan; Alexey G Mukhin; Ali Bozkurt; Nicholas Seneca; Dnyanesh Tipre; Christopher C DeNucci; Hidehiro Iida; D Bruce Vaupel; Andrew G Horti; Andrei O Koren; Alane S Kimes; Edythe D London; John P Seibyl; Ronald M Baldwin; Robert B Innis
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-10-02       Impact factor: 9.236

View more
  18 in total

1.  Chronic nicotine improves cognitive and social impairment in mice overexpressing wild type α-synuclein.

Authors:  Sudhakar R Subramaniam; Iddo Magen; Nicholas Bove; Chunni Zhu; Vincent Lemesre; Garima Dutta; Chris Jean Elias; Henry A Lester; Marie-Francoise Chesselet
Journal:  Neurobiol Dis       Date:  2018-06-01       Impact factor: 5.996

2.  Cerebral cortical and subcortical cholinergic deficits in parkinsonian syndromes.

Authors:  S Gilman; R A Koeppe; B Nan; C-N Wang; X Wang; L Junck; R D Chervin; F Consens; A Bhaumik
Journal:  Neurology       Date:  2010-05-04       Impact factor: 9.910

Review 3.  Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2017-12-08       Impact factor: 3.575

Review 4.  Molecular Imaging of the Cholinergic System in Parkinson's Disease.

Authors:  Nicolaas I Bohnen; Prabesh Kanel; Martijn L T M Müller
Journal:  Int Rev Neurobiol       Date:  2018-09-20       Impact factor: 3.230

Review 5.  Functional neuroimaging in Parkinson's disease.

Authors:  Martin Niethammer; Andrew Feigin; David Eidelberg
Journal:  Cold Spring Harb Perspect Med       Date:  2012-05       Impact factor: 6.915

6.  Enhancement of nicotinic receptors alleviates cytotoxicity in neurological disease models.

Authors:  Jun Kawamata; Syuuichirou Suzuki; Shun Shimohama
Journal:  Ther Adv Chronic Dis       Date:  2011-05       Impact factor: 5.091

7.  Single photon emission computed tomography experience with (S)-5-[(123)I]iodo-3-(2-azetidinylmethoxy)pyridine in the living human brain of smokers and nonsmokers.

Authors:  James Robert Brasić; Yun Zhou; John L Musachio; John Hilton; Hong Fan; Andrew Crabb; Christopher J Endres; Melvin J Reinhardt; Ahmet S Dogan; Mohab Alexander; Olivier Rousset; Marika A Maris; Jeffrey Galecki; Ayon Nandi; Dean F Wong
Journal:  Synapse       Date:  2009-04       Impact factor: 2.562

Review 8.  The cholinergic system and Parkinson disease.

Authors:  Nicolaas I Bohnen; Roger L Albin
Journal:  Behav Brain Res       Date:  2010-01-07       Impact factor: 3.332

9.  Imaging of cerebral α4β2* nicotinic acetylcholine receptors with (-)-[(18)F]Flubatine PET: Implementation of bolus plus constant infusion and sensitivity to acetylcholine in human brain.

Authors:  A T Hillmer; I Esterlis; J D Gallezot; F Bois; M Q Zheng; N Nabulsi; S F Lin; R L Papke; Y Huang; O Sabri; R E Carson; K P Cosgrove
Journal:  Neuroimage       Date:  2016-07-15       Impact factor: 6.556

10.  Cerebral amyloid angiopathy in Lewy body disease.

Authors:  K A Jellinger; J Attems
Journal:  J Neural Transm (Vienna)       Date:  2008-02-26       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.